Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry
Substantial loss of kidney function, kidney failure, and death were common events over a short period of time in patients with IgAN. Within health system populations, noncommercial health insurance and greater care utilization augmented risk prediction and could help to identify those who may benefit from closer monitoring and implementation of therapeutic interventions.
Authors
- Kenn B. Daratha (ORCID: https://orcid.org/0000-0002-9194-4140)
- Radica Z. Alicic (ORCID: https://orcid.org/0000-0002-5437-5700)
- Lindsey M. Kornowske
- Katherine R. Tuttle (ORCID: https://orcid.org/0000-0002-2235-0103)
- Keith C. Norris (ORCID: https://orcid.org/0000-0003-3071-0700)
- Cami R. Jones
- Wu Gong (ORCID: https://orcid.org/0000-0002-0336-7137)
- Mark Bensink (ORCID: https://orcid.org/0000-0002-5940-7898)
- Joshua J. Neumiller (ORCID: https://orcid.org/0000-0002-4734-7402)
- Christina Reynolds
- Susanne B. Nicholas
Institutions
- Washington State University Spokane (US)
- Providence College (US)
- University of Washington (US)
- Inland Northwest Health Services (US)
- Therapeutics Clinical Research (US)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1016/j.xkme.2025.100981
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Bayer
- Sanofi
- Gilead Sciences
- Dexcom
- CareDx
- Novo Nordisk
- George Institute for Global Health
- National Institutes of Health
- Centers for Disease Control and Prevention